# A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

> **NCT04704154** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 175 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Regorafenib, (Stivarga, BAY73-4506)
- **DRUG:** Nivolumab (Opdivo)

## Key facts

- **NCT ID:** NCT04704154
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-03
- **Primary completion:** 2023-03-09
- **Final completion:** 2024-03-29
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704154, "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04704154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*